Navigation Links
BioMS Medical announces first quarter 2008 results
Date:5/15/2008

million and escalating royalties on sales commensurate with the current stage of development of the product if dirucotide (MBP8298) is commercialized. The completion of the licensing agreement with Lilly resulted in a one time payment of a $9.0 million licensing bonus to Corporation personnel, paid in February, 2008.

Financial Results

The consolidated net loss for the first quarter ended March 31, 2008 was $6.7 million or ($0.07) per share compared to a consolidated net loss of $12.9 million or ($0.17) per share for the first quarter of the previous year.

Revenue for the three months ended March 31, 2008 was $12.8 million compared to $nil for the first three months of the previous year. The revenue is the result of recognizing a portion of the upfront payment received on the completion of the licensing agreement with Eli Lilly and Company.

Total consolidated expenses for the three months ended March 31, 2008 were $22.2 million compared to $13.3 million for the first three months of the previous year.

Research and development expenses for the first quarter ended March 31, 2008 totaled $13.1 million compared to $10.3 million for the first quarter of the previous year. The increase of $2.8 million is primarily attributable to: a one time licensing bonus payment of $3.4 million to research and development personnel, a decrease in drug manufacturing costs of $1.4 million and a decrease in clinical trial expenses of $1.7 million. It is expected that total research and development expenses will remain constant over the next two years as the MAESTRO-01 and MINDSET-01 clinical trials near completion while the MAESTRO-02 and MAESTRO-03 trials increase in number of patients under treatment.

General and administrative expenses were $8.7 million for the three months ended March 31, 2008 compared to $2.6 million for the three months ended March 31, 2007. The increase is primarily attributable to: a one time licensing bonus payment of $5.6
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- According to a new market report ... Asia to Witness Highest Growth by ... culture market was valued at US$ 586.1 Mn in 2014 ... 29.1% to account for US$ 2,717.6 Mn by 2020. ... 3D cell culture refers to a process ...
(Date:7/31/2015)... ... July 31, 2015 , ... Global Resorcinol ... premium industry insights on the global resorcinol industry. The report highlights the various ... vivid market scenarios and analysis of primary and secondary inputs from the existing ...
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
Breaking Biology Technology:Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4
... Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading ... from the oral hearing on 6 December 2011 at the European ... 1 536 827 " Further use of protein kinase N beta ... PKN3, protein kinase N beta, targeted by Silence,s lead program Atu027, ...
... 2011 Medicare carrier Palmetto GBA is proposing new processes ... molecular diagnostic tests (MDT) and laboratory-developed tests (LDT) in the ... marks the first known effort by a payer to address ... genetic tests and molecular diagnostics assays. These important ...
... 2011 Monsanto , a major biotech ... has been given the  Worst Company of 2011 ... environment. The award was given by  natural health ... Monsanto the worst company of 2011. ...
Cached Biology Technology:Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 2Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 3Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 4Why Medicare Carrier Proposes Major Changes in the Handling of Code Stacked Molecular Test Claims is Topic of December 20 Audio Conference 2Monsanto Declared Worst Company of 2011 by NaturalSociety 2
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
(Date:7/8/2015)... July 8, 2015 The consumer products ... summer,s must have products such as wearables, smart wallets & ... for biometrics based devices continues to rapidly grow.  Biometrics & ... NXTD ), Google Inc. (NASDAQ: GOOG ), Apple ... ), GoPro, Inc. (NASDAQ: GPRO ) and Baidu Inc. ...
(Date:7/2/2015)... 25, 2015 Research and ... "Next Generation Biometrics Market by Application, Technology, Function ... to their offering. The next generation biometrics ... at a CAGR of 17.9% between 2015 and 2020 ... for the market. Safran SA ( ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... through the 133 page record of the 2006-2007 activities of ... youll see why they recently took home the nations most ... fundraiser. Youll find the detailed lesson plans that honor ... 75 fifth grades at Spreckels elementary school last year. Youll ...
... scientists including researchers at Cold Spring Harbor Laboratory (CSHL) ... neural stem and progenitor cells (NPCs) to be tracked, ... important advance could lead to significantly better diagnosis and ... neurological and psychiatric disorders. The biomarker is a ...
... major role in an international scientific team that has ... related fruit fly species. As well has having implications ... immune systems -- the analysis paves the way for ... results of the research, the Cornell scientists coordinated one ...
Cached Biology News:UC-San Diego Engineering Honor Society wins most outstanding chapter award 2Team of scientists develops non-invasive method to track nerve-cell development in live human brain 2International team compares 12 fruit fly genomes 2International team compares 12 fruit fly genomes 3
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Phospho-SEK1/MKK4 (Thr261) Antibody...
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
BACE (CT) rabbit polyclonal antibody...
Biology Products: